Screener / SEC EDGAR /CIK 0001739104 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Elanco Animal Health Inc ELAN

Compare with peers Embed
The 10-K against last year's

178 changes: 25 added, 21 removed, 128 reworded, 4 quiet changes

10-K Feb 24, 2026 vs Feb 25, 2025

10-K 0001739104-26-000012 (Feb 24, 2026) vs 10-K 0001739104-25-000014 (Feb 25, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

170 paragraphs · 6 new · 78 reworded · 6 gone · 10-K Feb 24, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 52 · 50% changed Every version of it
We are continuing rely on sophisticated IT systems and infrastructure to enhance a number of manage and operate our business processes, including our financial reporting and supply chain processes and from whom we obtain IT systems. business. We have made, and will continue to make, significant configuration, process and data changes within many of the IT systems we use. If our IT systems and processes are not sufficient to support our business and financial reporting functions, needs, or if we fail to properly implement our new business processes, our financial reporting may be delayed or inaccurate and, as a result, our business, financial condition and results of operations may be materially adversely affected. Even if we are able ability to successfully configure and change our systems, all technology systems, even with implementation of security measures, are vulnerable to disability, failures and cybersecurity risks, including unauthorized access. If our IT systems or our service providers' IT systems were to fail or be breached, this could materially adversely affect our reputation conduct business and our ability to perform critical business functions, and sensitive and confidential data could be compromised. relationships with our customers or other key
Paragraph 144 · 50% changed Every version of it
The intellectual property positions of animal health businesses frequently involve complex legal and factual questions, and an issued patent does not guarantee us the right to practice the patented technology indemnify a distributor, licensor or develop, manufacture or commercialize the patented product. For example, while other third party. Further, we generally enter into proprietary information agreements with our employees and third parties, which assign intellectual property rights to us, these agreements may not be honored or may not effectively assign intellectual property rights to us under the local laws of some countries or jurisdictions. We cannot be certain that a competitor or other third party does not have, or will not obtain rights to, intellectual property that may prevent us from manufacturing, developing or marketing certain products, regardless of whether we believe such intellectual property rights are valid and enforceable or we believe we would otherwise be able to develop a more commercially successful product, which may materially adversely affect our business, financial condition and results of operations. enforceable.
Paragraph 34 · 49% changed Every version of it
For example, as a result of our acquisition of Bayer Animal Health, we integrated each business' distinct enterprise resource planning (ERP) systems into one primary platform, a process that was substantially completed in 2023. ERP integrations have inherent risks, which can complicate our business operations and potentially lead to breakdowns in data integrity and may preclude our ability to supply products for a period of time, as was the case with this aforementioned ERP integration in April 2023. To the extent future ERP or other integration or carve-out activities are required for future acquisitions, divestitures or joint ventures, we could be required to deploy significant resources and attention to these efforts. If we are unable to successfully integrate or carve-out our systems to support critical business operations of acquired or divested businesses or to produce information for business decision-making activities, we could experience a material adverse impact on our business, including increased costs, data integrity and/or cybersecurity risks and an inability to timely and accurately report our financial results.
Paragraph 146 · 48% changed Every version of it
Our long-term success depends on our ability to market innovative and competitive products. products, many of which are based on or incorporate proprietary information. We rely on and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection, as well as confidentiality and license agreements with our employees and others, to protect our although the intellectual property positions of animal health businesses frequently involve complex legal and proprietary rights. If we fail factual questions, and an issued patent does not guarantee us the right to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from using our proprietary technologies practice the patented technology or from marketing products that are very similar develop, manufacture or identical to ours. commercialize the patented product.
Paragraph 129 · 47% changed Every version of it
We have made significant progress in recent years in gaining acceptance of farm animal sustainability products. However, throughout 2025, the degree U.S. presidential administration has implemented significant changes to the size and scope of acceptance for the federal government, and among these products is uncertain, and one or more markets may resist changes, certain previously authorized government incentives focused on the adoption of new products for the sole purpose of sustainability have been frozen or rescinded. Given the absence of government incentives as a result of these changes, we believe the adoption rate of Bovaer, one of our farm animal sustainability products, has been tempered. As a result, we are continuing to make investments to support Bovaer's adoption beyond its initial launch, and we expect that additional studies, which are underway, and a potential expansion of claims may be required to expand Bovaer's value proposition and achieve its expected potential. Ultimately, the degree of acceptance for Bovaer and other products for the sole purpose of sustainability is uncertain, especially in the absence of government subsidies incentivizing such adoption. As a result, adoption, and there can be no assurance we will be able to expand the use of our sustainability products in these the U.S. or other markets. In the event we are unable to do so, we could be subject to lower than expected sales of these products, sales at prices that contribute minimally, or even negatively, to our gross margin, inventory and/or other asset write-offs, increased investments in our R&D and sales and marketing efforts to support these products, among other potential adverse impacts to our results of operations.
Paragraph 134 · 47% changed Every version of it
sales and increased costs. Given the international nature of our supply chain, in certain instances we, our customers or other key business partners depend on suppliers and service providers based in China, Canada, Mexico and other foreign jurisdictions. Tariffs, trade protection measures, import or export regulations or other restrictions imposed or maintained on our current or future products, customers or other key business partners by the United States, China, Canada, Europe, Mexico or other countries countries. For example, on February 20, 2026, the U.S. Supreme Court issued a decision concluding that the International Emergency Economic Powers Act does not provide authority for the U.S. President to impose tariffs. Subsequently, new tariffs were imposed pursuant to Section 122 of the Trade Act of 1974. The ultimate financial impact of these and other decisions cannot be reasonably estimated at this time; however, any significant changes in tariffs or trade regulation could have a material adverse effect on our business, financial condition and results of operations.
Paragraph 133 · 45% changed Every version of it
Meaningful changes in laws, tariffs, trade agreements and policies governing international trade in the territories and countries where we and our customers do business could negatively impact us and our customers’ businesses and adversely affect our results of operations. Tariffs in key markets can change significantly and without notice, as has occurred throughout 2025 and into 2026. Significant trade disruptions, or the establishment or increase of tariffs, trade protection measures or restrictions and/or any retaliatory actions from foreign governments, could result in lost sales and increased costs. Given the international nature of our supply chain, in certain instances we, our customers or other key business partners depend on suppliers and service providers based in China, Canada, Europe, Mexico and other foreign jurisdictions. Changes to U.S. trade policy throughout 2025 have resulted in new or higher tariffs on goods imported from these and other countries, and some countries have imposed retaliatory tariffs on imports from the U.S. While pharmaceutical products have been largely exempt from the U.S. tariffs imposed in 2025, it remains uncertain if this will continue to be the case, and pharmaceutical products are not exempt from all tariffs imposed outside of the U.S. We will continue to monitor developments and evaluate the potential impact from any new or changing tariffs, trade protection measures, extraterritorial regulation, import or
Paragraph 38 · 42% changed Every version of it
We have, from time to time, restructured or made other adjustments to our workforce and manufacturing footprint. Execution of such organizational changes can involve significant costs, including expenses related to severance, asset impairments and other potential charges. For example, in 2024 December 2025, we implemented a initiated the 2025 Restructuring Plan to support margin expansion, optimize our manufacturing and R&D footprints and further invest in innovation. We incurred $155 million of pre-tax charges associated with this restructuring plan in 2025, with an additional $25 million to improve operational efficiencies and better align our organizational structure with current business needs, top strategic priorities and key growth opportunities $30 million expected to be incurred in 2026 (see Note 5. Asset Impairment, Restructuring and Other Special Charges to the consolidated financial statements for further information).

MD&A

78 paragraphs · 19 new · 43 reworded · 15 gone · 10-K Feb 24, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 41 · 50% changed
Amounts recorded to asset impairment, restructuring and other special charges during the year ended December 31, 2024, 2025, included a $53 $155 million impairment charge related to the write-off of a pet health IPR&D asset, $44 million of costs associated with the restructuring plan discussed above, $18 2025 Restructuring Plan, of which $116 million of acquisition related to expected cash-based severance costs and divestiture-related charges, $39 million related primarily to non-cash impairment charges associated with our aqua business divestiture, animal studies R&D facilities in Monheim, Germany, and $15 million of our manufacturing facility in Kansas City, Kansas. Additional amounts recorded to asset impairments tied to the financial difficulties of our former contract manufacturing supply partner, TriRx, the largest of which was impairment, restructuring and other special charges in 2025 included a $12 $47 million impairment of a contract marketed product intangible asset during the fourth quarter due to a decline in projected sales of a product group acquired in a past acquisition and $16 million in impairments recorded during the third quarter related to a favorable supply agreement. two early-stage capital projects that were indefinitely suspended.
Paragraph 48 · 50% changed
Other expense, net for the years ended December 31, 2025 and 2024, primarily consisted of foreign currency exchange losses. Other expense, net for the year ended December 31, 2024, primarily consisted of foreign currency exchange losses and also included an $8 million write-down of the retained equity interest in our previously divested BiomEdit R&D platform (see Note 4. Acquisitions, Divestitures and Other Arrangements to the consolidated financial statements for further information). Other expense, net for the year ended December 31, 2023, primarily consisted of foreign currency exchange losses of $50 million and settlement provisions of $15 million related to the Seresto class action lawsuit and $12.5 million for a possible resolution or settlement with the SEC related to potential disclosure claims, which was ultimately settled in 2024 for $15 million, with the increase in the provision recorded within other expense, net in 2024 (see Note 16. Commitments and Contingencies to the consolidated financial statements for further information). previous divestiture.
Paragraph 31 · 47% changed
R&D expenses Pet health revenue increased $17 $157 million, or 5%, in 2024 7%, compared to 2023, 2024, driven by higher volumes and a 2% increase in pricing. Higher volumes were primarily driven by higher employee-related expenses new products, led by Credelio Quattro, Zenrelia and timing AdTab, including the impacts of project costs. initial stocking.
Paragraph 50 · 46% changed
Income tax expense was $8 million in 2025 compared to $150 million in 2024 compared to $36 million in 2023. Income tax expense in 2024 included approximately $170 million related to income tax associated with the taxable gain on the divestiture of our aqua business. 2024. Our effective tax rate of 31% (3.5)% in 2024 2025 differed from the statutory income tax rate primarily due to the income tax associated with the gain on the divestiture of our aqua business, jurisdictional earnings mix of income in higher tax non-U.S. jurisdictions and losses an increase in our reserve for which no uncertain tax benefit was recognized. These factors were positions, partially offset by our ability to realize the tax benefit from the remeasurement of certain net operating loss carryforwards and other deferred tax attributes, which had historically been offset by a valuation allowance, positions throughout the year due to the gain on the sale of our aqua business, and the recognition of certain state foreign tax credits. rate changes.
Paragraph 14 · 42% changed
We incurred $44 million of charges associated with the restructuring plan in 2024, the majority relating to cash-based severance costs. The restructuring plan is expected to result in annualized net savings of $30 to $35 million. See Note 5. Asset Impairment, Restructuring and Other Special Charges to the consolidated financial statements for further information. information on the 2025 and 2024 Restructuring Plans.
Paragraph 63 · 40% changed
Cash used for financing activities was $275 million for the year ended December 31, 2025, compared to $1,492 million for the year ended December 31, 2024, compared to $83 million for the year ended December 31, 2023. In 2024, we repaid $1,600 million of term loan debt, $200 million, net on our Revolving Credit Facility and $25 million, net on our Securitization Facility. These debt repayments were partially offset by proceeds of $350 million from the issuance of our Incremental Term Facility due 2031 in August 2024. Cash used for financing activities during 2023 primarily reflected in 2025, included $563 million in net repayments of long-term borrowings, partially enabled by the repayment of our previously outstanding 4.272% Senior Notes due 2023, partially offset by $200 $290 million of net borrowings on proceeds from our Revolving Credit Facility sale of future revenue (see Note 7. Debt and $125 million of net borrowings on our Securitization Facility. See Note 8. Debt Finance Lease Liability to the consolidated financial statements for further information related to our on current year debt related borrowing financing and repayment activity. activity and Note 10. Liability for Sale of Future Revenue to the consolidated financial statements for further information on our sale of future revenue).
Paragraph 37 · 39% changed
R&D Marketing, selling and administrative expenses increased $17 $116 million, or 5%, in 2024 9%, compared to 2023, 2024, primarily driven by higher employee-related expenses strategic investments in the global launches of new products and timing of project costs. increased selling costs, corresponding to increased revenue.
Paragraph 46 · 37% changed
Interest expense, net of capitalized interest decreased $42 $15 million in 2024 compared to 2023, primarily due to 2024. This decrease was driven by lower average outstanding debt balances given our debt repayment activity in during the current year year. This decrease was partially offset by the combined impacts from the $33 million of imputed interest on our liability for sale of future revenue (see Note 8. Debt 10. Liability for Sale of Future Revenue to the consolidated financial statements for further information), an $11 million increase in financing costs, including the non-cash write-offs of previously deferred debt issuance costs, as compared to 2024, as well as increased $8 million of interest income from expense related to our net investment hedges, which we record as contra-interest expense, net of capitalized interest new corporate headquarters finance lease (see Note 9. Financial Instruments 13. Leases to the consolidated financial statements for further information). These decreases were partially offset by a $12 million non-cash charge in 2024 related to the write-off of previously deferred financing costs, given our early debt repayments.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Legal Proceedings238 words changed in this paragraph; it is 35% similar to last year's version.
On October 7, 2024, a putative securities class action lawsuit captioned Joseph Barpar v. Elanco Animal Health Inc., et al. (Barpar) was filed in the United States District Court for the District of Maryland against Elanco and two of its executives. Barpar alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and specifically alleges that Elanco and the two executives made materially false and/or misleading statements and/or failed to disclose certain facts about the safety of and labeling for our Zenrelia® product, as well as the approval and launch timelines for Zenrelia and our Credelio Quattro™ product. The plaintiff purports purported to represent purchasers of Elanco securities between November 7, 2023 and June 26, 2024. On November 1, 2024, March 21, 2025, plaintiff filed an amended complaint that extended the time period for which the plaintiff purported to represent purchasers of Elanco securities to between May 9, 2023 and June 26, 2024. The amended complaint also removed allegations concerning the approval and launch timelines for our Credelio Quattro product. On May 20, 2025, we filed a shareholder derivative action captioned Lawrence Hollin v. Lawrence E. Kurzius, et al. was filed in the United States District Court for the District of Maryland against current members of Elanco's Board of Directors and senior management, alleging claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and state law claims for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment and waste of corporate assets, based on allegations substantially similar motion to the allegations in the putative class action complaint in Barpar. We are vigorously defending our positions in connection with both actions. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at dismiss this time, the ultimate resolution cannot be predicted. case.

Source: Item 3, via Note 16 – Commitments and Contingencies, 10-K 0001739104-26-000012 vs Item 3, via Note 16 – Commitments and Contingencies, 10-K 0001739104-25-000014

Risk Factors221 words changed in this paragraph; it is 45% similar to last year's version.
We are subject to income taxes in the U.S. and numerous other jurisdictions. Future results of operations could be adversely affected by changes in our effective tax rate as a result of a change in the mix of earnings between U.S. and non-U.S. jurisdictions or among jurisdictions with differing statutory tax rates, and the enactment of new tax laws, such as those stemming from the Organization for Economic Cooperation and Development's Pillar Two initiative, or changes to existing laws, regulations, or treaties (or their interpretation) in the U.S. or foreign jurisdictions where we operate. Such changes could include modifications to tax rates, deductions, credits or the U.S. taxation of international income, and could be applied retroactively. In addition, changes in our overall profitability, changes in tax laws or treaties or in their application or interpretation, changes in tax rates, changes in GAAP, changes in the valuation of deferred tax assets and liabilities, the results of audits and examinations of previously filed tax returns and continuing assessments of our tax exposures. In connection with the Base Erosion and Profit Shifting (BEPS) Integrated Framework provided by the Organization for Economic Cooperation and Development (OECD), the OECD introduced a framework to implement a global minimum corporate tax of 15%, referred to as Pillar Two exposures could individually or the minimum tax directive. Many aspects of the minimum tax directive went into effect in 2024, with certain remaining impacts to become effective in 2025. While it is uncertain whether the U.S. will enact legislation to adopt the minimum tax directive, certain countries in which we operate have adopted legislation, and other countries are in the process of introducing legislation to implement the minimum aggregate have a material adverse effect on our income tax directive. Our analysis is ongoing as the OECD continues to release additional guidance and countries implement legislation. While the adoption of Pillar expense.

Source: Item 1A, 10-K 0001739104-26-000012 vs Item 1A, 10-K 0001739104-25-000014

MD&A184 words changed in this paragraph; it is 32% similar to last year's version.
Cash used for financing investing activities was $1,492 $279 million for the year ended December 31, 2024, 2025, compared to $83 cash provided by investing activities of $1,158 million for the year ended December 31, 2023. In 2024, we repaid $1,600 million of term loan debt, $200 million, net on our Revolving Credit Facility and $25 million, net on our Securitization Facility. These debt repayments were partially offset by proceeds of $350 million from the issuance of our Incremental Term Facility due 2031 in August 2024. Cash used for financing investing activities during 2023 primarily reflected the repayment in 2025 largely consisted of our previously outstanding 4.272% Senior Notes due 2023, partially offset by $200 $276 million of net borrowings on our Revolving Credit Facility purchases of property and $125 equipment and software, which was $129 million higher than 2024. This increase in purchases of net borrowings on our Securitization Facility. See Note 8. Debt property and equipment and software primarily related to the consolidated financial statements for expansion of our monoclonal antibody manufacturing facility in Elwood, Kansas, as well as multiple capital projects at other of our global manufacturing facilities. Additionally, in August 2025 we purchased approximately 56 acres of land to further information related to our debt related borrowing and repayment activity. vision of creating the One Health Innovation District research hub centered around our new corporate headquarters in Indianapolis, Indiana.

Source: Item 7, 10-K 0001739104-26-000012 vs Item 7, 10-K 0001739104-25-000014

Accounting Policies86 words changed in this paragraph; it is 70% similar to last year's version.
Similar to goodwill, indefinite-lived intangible assets, which primarily represent IPR&D in-process research and development (IPR&D) assets acquired from prior business combinations, are not amortized, but rather are reviewed annually for impairment during the fourth quarter, or more frequently in the event of a triggering event. We utilize an income approach for determining the estimated fair value of indefinite-lived intangible assets upon acquisition and as needed for our evaluations of potential impairment. For valuation of IPR&D assets, we apply a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows from the asset. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to present value using an appropriate discount rate. Acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and, if not impaired, are transferred to marketed products (see Other Long-Lived Assets discussion below) and amortized over their estimated economic life.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001739104-26-000012 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001739104-25-000014

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of ELAN's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 25, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
produce information for business decision-making activities, we could experience a material adverse impact on our business, including increased costs, data integrity and/or cybersecurity risks and an inability to timely and accurately report our financial results.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
business partners could be harmed, perhaps materially so. Further, if an IT system failure or outage were to delay or impair our ability to timely report our financial condition and results of operations, our reputation and/or relationships with shareholders could be harmed.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
We also have a series of cross-currency interest rate swaps (net investment hedges) to help mitigate the impact of currency rate fluctuations on our operations in Switzerland with tenors in August and November of 2026 and February of 2027. As of December 31, 2025, these net investment hedges have generated net losses of approximately $155 million due to exchange rate movements between the U.S. dollar and Swiss franc, and we are exposed to additional net losses to the extent the U.S. dollar weakens further against the Swiss franc. Net investment hedges present settlement exposure to the extent they remain in a loss position at maturity. To the extent we must use cash on hand to settle these instruments, this could adversely affect our financial condition and cash flows. See Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk for further discussion around our exposure to potential changes in foreign currency exchange rates.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
As a global company, we are subject to various state, federal and international laws and regulations, including regulations relating to the development, quality assurance, manufacturing, importation, distribution, marketing and sale of our products. These laws and regulations, and the approach taken by relevant authorities to enforce them, are continuously evolving. For example, changes to environmental risk assessments associated with pet parasiticides in Europe are currently being evaluated and could be proposed or implemented in the near future. Additionally, in the EU, the Veterinary Medicinal Products Regulation updated the rules related to the authorization and use of veterinary medicines effective January 28, 2022. These updated rules limit the use of antibiotics, tighten importation rules, impose different pharmacovigilance reporting standards and impose new product packaging
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
Generic competitors are becoming more aggressive in terms of launching products before patent rights expire, and, because of attractive pricing, sales of generic products are an increasing percentage of overall animal health sales in certain regions. If animal health customers increase their use of new or existing generic products, we may be forced to lower our prices and/or provide discounts or rebates in order to compete with generic products. In such event, our business, financial condition and results of operations could be materially adversely affected.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
For example, in September 2024 one of our contract manufacturing supply partners, TriRx Speke, entered into trading administration, a formal insolvency process in the U.K. In November 2024, in an effort to minimize supply disruption, we acquired this manufacturing site from TriRx Speke for approximately $36 million (see Note 4. Acquisitions, Divestitures and Other Arrangements to the consolidated financial statements for further information). In addition to this unanticipated capital outlay, we also expect increased integration and operational costs in 2025 related to operating this site.
Read it in 10-K Feb 25, 2025 at sec.gov
Show the other 56
RemovedRisk Factors
Two did not have a material impact to income taxes in 2024, to the extent additional changes take place in the countries in which we operate, it is possible these legislative changes may have an adverse impact on our effective tax rates and the amount of income tax we are required to pay.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
Additionally, lawsuits seeking actual damages, injunctive relief and/or restitution for allegedly deceptive marketing were filed against us arising out of the use of Seresto, a non-prescription flea and tick collar for cats and dogs, based on media reports alleging that the collar caused injury and death to pets. In 2023, the EPA announced the completion of its comprehensive, multi-year review of the Seresto flea and tick collar and confirmed the continued registration of the collar. However, if any similar claims with respect to our products are resolved adversely to us, or if a regulatory agency determines that a recall or cancellation of registrations of any of our products is necessary, such action could cause harm to our reputation, reduce our product sales, result in monetary penalties and other costly remedies against us, and could therefore have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
We are increasingly dependent on our IT systems as many of our office workers who work partially or primarily remotely, rely on third-party applications to perform their job duties and are processing information through our network via their home networks, which may be less secure. As such, our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data and the ability of our employees to follow our cybersecurity policies and protocols.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedRisk Factors
Future results of operations could be adversely affected by changes in our effective tax rate as a result of a change in the mix of earnings between U.S. and non-U.S. jurisdictions or among jurisdictions with differing statutory tax rates, and the enactment of new tax laws, such as those stemming from the Organization for Economic Cooperation and Development's Pillar Two initiative, or changes in our overall profitability, changes in tax laws to existing laws, regulations, or treaties or in (or their application or interpretation, changes in tax rates, changes in GAAP, changes interpretation) in the valuation of deferred tax assets and liabilities, the results of audits and examinations of previously filed tax returns and continuing assessments of our tax exposures. U.S. or foreign jurisdictions where we operate.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Future results of operations could be adversely affected by changes in our effective tax rate as a result of a change in the mix of earnings between U.S. and non-U.S. jurisdictions or among jurisdictions with differing statutory tax rates, In addition, changes in our overall profitability, changes in tax laws or treaties or in their application or interpretation, changes in tax rates, changes in GAAP, changes in the valuation of deferred tax assets and liabilities, the results of audits and examinations of previously filed tax returns and continuing assessments of our tax exposures. exposures could individually or in the aggregate have a material adverse effect on our income tax expense.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We rely on and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection, as well as confidentiality and license agreements with our employees and others, to protect our although the intellectual property positions of animal health businesses frequently involve complex legal and proprietary rights. factual questions, and an issued patent does not guarantee us the right to practice the patented technology or develop, manufacture or commercialize the patented product.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
A new For example, a putative securities class action amended complaint was also filed against us in 2024, along with a subsequent related shareholder derivative securities claim, claims, alleging material misstatements or and/or omissions concerning the safety and safety, profitability, labeling of Zenrelia and the approval and launch timelines for Zenrelia timeline of Zenrelia, as well as its differentiation in the marketplace, and Credelio Quattro along with the breach of fiduciary duties regarding those allegations, respectively. allegations.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If our IT systems and processes are not sufficient to support our business and financial reporting functions, needs, or if we fail to properly implement our new business processes, our financial reporting may be delayed ability to conduct business and our relationships with our customers or inaccurate and, as a result, our business, financial condition and results of operations may be materially adversely affected. other key
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Such sales, or the perception in the market that holders of In addition, if we sell a large substantial number of shares intend to sell shares, could depress of common stock in the public markets, the market price of our common stock could be negatively impacted and could impair our ability to raise future capital through the sale of additional equity securities.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If we are unable to successfully integrate or carve-out our systems to support critical business operations of acquired or divested businesses or to produce information for business decision-making activities, we could experience a material adverse impact on our business, including increased costs, data integrity and/or cybersecurity risks and an inability to timely and accurately report our financial results.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
As a result, Ultimately, the degree of acceptance for Bovaer and other products for the sole purpose of sustainability is uncertain, especially in the absence of government subsidies incentivizing such adoption, and there can be no assurance we will be able to expand the use of our sustainability products in these the U.S. or other markets.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Despite these efforts and precautions, we may be unable to prevent a third party from copying or otherwise obtaining and using our trade secrets or other intellectual property without authorization, and legal remedies as such agreements may not adequately compensate be honored, or may not effectively assign intellectual property rights to us for under the damages caused by such unauthorized use. local laws of some countries or jurisdictions.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We Further, we cannot be certain that a competitor or other third party does not have, or will not obtain rights to, intellectual property that may prevent us from manufacturing, developing or marketing certain products, regardless of whether we believe such intellectual property rights are valid and enforceable or we believe we would otherwise be able to develop a more commercially successful product, which may materially adversely affect our business, financial condition and results of operations. enforceable.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
There Effective trademark, service mark, trade dress or related protections may not be available in every country in which our products and services are available, and there can be no assurance that the steps we have taken and will take to protect our proprietary rights in our brands and trademarks will be adequate or that third parties will not infringe, dilute or misappropriate our brands, trademarks, trade dress or other similar proprietary rights.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In addition, certain of our credit facilities require us to comply with a net total leverage ratio, an interest coverage ratio and a minimum fixed charge coverage ratio under certain circumstances other covenants specific to the underlying composition of our U.S. accounts receivables portfolio (see Note 8. 7.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
The However, the impact of changes in regulations and market preferences regarding the use of antibiotics and productivity products in farm animals could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
We also expect there will could be new laws or regulations concerning the use of AI technology, which might be burdensome to comply with and may limit our ability to use this technology.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Befrena: In December 2025, we received final approval from the USDA for Befrena, a new anti-IL31 monoclonal antibody injection targeting canine allergic and atopic dermatitis. We anticipate launching Befrena in the second quarter of 2026.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Restructuring Activities: In December 2025, our Board of Directors authorized a restructuring plan (the 2025 Restructuring Plan) to support margin expansion, optimize our global footprint and further invest in innovation. Specifically, the 2025 Restructuring Plan targeted an expected 2026 closure of the animal studies portion of our R&D facilities in Monheim, Germany, while also expanding our R&D organization in Indianapolis, Indiana, among other changes to our R&D organization. The 2025 Restructuring Plan is also expected to result in our exit from certain farm animal implant products and the related closure of our manufacturing facility in Kansas City, Kansas, in 2026. In total, the 2025 Restructuring Plan is expected to result in a global headcount reduction of approximately 300 employees, with an additional approximately 300 employees whose positions will be replaced with positions in growth areas or in lower-cost geographies. In 2025, we incurred $155 million of charges associated with the 2025 Restructuring Plan, of which $116 million related to expected cash-based severance costs and $39 million related primarily to non-cash impairment charges associated with our animal studies R&D facilities in Monheim, Germany, and our manufacturing facility in Kansas City, Kansas. We expect a further $25 million to $30 million of restructuring charges in 2026, primarily related to the remaining shut-down costs for our Monheim, Germany, and Kansas City, Kansas, facilities. The 2025 Restructuring Plan is expected to result in savings of approximately $25 million in 2026 and approximately $60 million in 2027.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Trade Environment and Other U.S. Government Initiatives: Changes to U.S. trade policy throughout 2025 and into 2026 have resulted in new or higher tariffs on goods imported from numerous countries, and some countries have imposed retaliatory tariffs on imports from the U.S. While pharmaceutical products are largely exempt from the U.S. tariffs imposed, it remains uncertain if this will continue to be the case, and pharmaceutical products are not exempt from all tariffs imposed outside of the U.S. Aside from quarterly fluctuations in revenue due to some customers' accelerated purchases of certain farm animal products internationally in anticipation of future tariff increases, these new and increased tariffs did not have a material impact on our results of operations during the year ended December 31, 2025. On February 20, 2026, the U.S. Supreme Court issued a decision concluding that the International Emergency Economic Powers Act does not provide authority for the U.S. President to impose tariffs. Subsequently, new tariffs were imposed pursuant to Section 122 of the Trade Act of 1974. While the ultimate financial impact of these and other decisions cannot be reasonably estimated at this time, we will continue to closely monitor the trade policies in the countries in which we operate and/or from where we import products and continue to take actions, where possible, to mitigate the impacts on our business.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Further, throughout 2025, the U.S. presidential administration has implemented significant changes to the size and scope of the federal government. Among these changes, certain previously authorized government incentives focused on the adoption of new products for the sole purpose of sustainability have been frozen or rescinded. While we have made significant progress in recent years in gaining acceptance of farm animal sustainability products, we believe the adoption rate of Bovaer, one of our farm animal sustainability products, has been tempered given the absence of government incentives focused on such adoption. As a result, we are continuing to make investments to support Bovaer's adoption beyond its initial launch, and we expect that additional studies, which are underway, and a potential expansion of claims may be required for Bovaer to achieve its expected potential. We continue to monitor the impact these changes are having on our current business and on the adoption ramp of Bovaer, although the potential longer-term impact to us remains uncertain.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Debt Refinancing: In October 2025, we refinanced our previously outstanding Term Loan B due 2027, paying off the $2,102 million balance in full with the proceeds from three new debt facilities – a €400 million Euro Term Loan due 2029, $1,100 million Term Loan B due 2032 and $540 million Incremental Term Facility due 2032 – and cash on hand. These refinancing activities extend our debt maturity profile and are expected to lower future cash paid for interest. See Liquidity and Capital Resources discussion below, as well as Note 7. Debt and Finance Lease Liability to the consolidated financial statements, for further information.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Sale of Future Revenue: In May 2025, we executed a Purchase and Sale Agreement (PSA) with affiliates of Blackstone, pursuant to which we received proceeds of $295 million in exchange for the rights to the proceeds from qualifying future royalties and sales milestone payments owed to us by Tarsus Pharmaceuticals, Inc. (Tarsus) based on their net sales of XDEMVY® (lotilaner ophthalmic solution) 0.25%, a medical treatment for Demodex blepharitis in humans. Rights to qualifying royalties sold to Blackstone apply to net sales of XDEMVY in the U.S. from April 1,
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
2025 through August 24, 2033. We retain the rights to all royalty payments on net sales outside the U.S. and any royalties due on U.S. net sales after August 24, 2033. These net proceeds were utilized to repay previously outstanding debt. See Note 10. Liability for Sale of Future Revenue to the consolidated financial statements for further information.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Corporate Headquarters Lease: In June 2025, we commenced a five-year finance lease for our new corporate headquarters in Indianapolis, Indiana. This lease contains both an option for Elanco to purchase the headquarters facility and a put right for the landlord to put the facility to us, both of which, if exercised, would occur at the end of the five-year lease term for $250 million. It is our current expectation that we will exercise our purchase option at the end of the lease term. As of December 31, 2025, the total finance lease liability was $255 million, with a corresponding right-of-use (ROU) asset of $223 million, net of accumulated amortization. See Note 7. Debt and Finance Lease Liability and Note 13. Leases to the consolidated financial statements for further information.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
shifting market dynamics, payment terms we extend, which are subject to internal policies, blackout shipping periods due to system downtime, implementations and integrations and procedures and environmental factors beyond our control.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party and royalty revenue. In May 2025, we entered into an agreement to sell certain qualifying royalties, among other potential future cash flows for proceeds of $295 million in cash. While we are no longer entitled to these qualifying royalties, we are required under GAAP to continue recognizing them as revenue. For the year ended December 31, 2025, royalty revenue associated with this arrangement, which is reflected within Contract Manufacturing and Other in the table above, totaled $19 million. See Note 10. Liability for Sale of Future Revenue to the consolidated financial statements for additional information.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Gross profit increased $157 million, or 6%, compared to 2024, driven by increased revenue, while gross margin percentage was relatively flat at 55.0%, compared to 54.9% in 2024. The favorable impacts from improved pricing and the productivity benefits from increased sales volumes were offset by the impacts of inflation and higher manufacturing costs.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
Aqua Business Divestiture: On July 9, 2024, we closed the sale of our aqua business to a subsidiary of Merck Animal Health, for $1,294 million in cash. We utilized a vast majority of these proceeds to repay previously outstanding term loan debt, thereby reducing our leverage and expected future interest expense. Our aqua business included products across both warm-water and cold-water species and generated revenue of $81 million in 2024, through the divestiture date, and $175 million in 2023. Strategically, this divestiture has allowed us to prioritize our investments in larger markets with greater long-term earnings potential.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Assets sold included inventories, real property and equipment, including our manufacturing sites in Canada and Vietnam, and certain intellectual property, technology and other intangible assets, including marketed products.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Acquisition and Integration Activity: In November 2024, we acquired a manufacturing facility in Speke, U.K., including its workforce and related assets such as inventory and property and equipment, from a former contract manufacturing supply partner, TriRx Speke Ltd (TriRx Speke), for $36 million.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
In 2023, we acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest) and certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil). Additionally, we successfully completed the integration of the Bayer Animal Health business into our ERP system, including the build out of processes and systems to support our global organization. See Note 4. Acquisitions, Divestitures and Other Arrangements and Note 5. Asset Impairment, Restructuring and Other Special Charges to the consolidated financial statements for further information on these acquisition and integration activities.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Pet health revenue increased $39 million, or 2%, driven by a 3% increase in pricing, partially offset by slightly lower volumes. Volume decreases were primarily due to competitive pressure on certain products in the U.S. veterinary channel and purchasing patterns of certain over-the-counter (OTC) products by U.S. retailers. These decreases were partially offset by revenue from new products and improved demand for retail parasiticide products in certain European markets, including Spain.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Cost of sales increased $72 million in 2024 as compared to 2023, and cost of sales as a percentage of revenue increased from 44% to 45% year-over-year. These increases were due to a combination of inflation, planned reduced throughput at certain manufacturing sites and product mix associated with the divestiture of our aqua business, partially offset by increased pricing.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Amortization of intangible assets decreased $21 million in 2024 compared to 2023. This decrease was primarily driven by changes in foreign currency exchange rates and the elimination of amortization related to our aqua business intangible assets, which met the criteria to be classified as held for sale on February 1, 2024, at which date amortization of these intangible assets ceased. See Note 4. Acquisitions, Divestitures and Other Arrangements to the consolidated financial statements for further information.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
As previously disclosed, there was a sharp increase in long-term treasury rates during the third quarter of 2023, and as a result, we assessed our long-lived assets, including goodwill, for impairment. Due principally to an increased discount rate assumption, which was driven by the sharp increase in long-term treasury rates, our quantitative goodwill impairment test resulted in a $1,042 million pre-tax impairment charge. For additional information, see Note 11. Goodwill and Intangibles to the consolidated financial statements.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Foreign currency exchange losses were lower in 2024 in large part due to the restructuring plan actions in the current year, which impacted how we operate in and sell into the Argentina market, among others, reducing our foreign currency exposure in these markets.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
The negative effective tax rate in 2023 differed from the statutory income tax rate primarily due to the recognition of the goodwill impairment charge recognized in 2023 that was non-deductible for income tax purposes in most of the impacted jurisdictions, as well as an increase in our valuation allowance, primarily attributable to the likelihood of not realizing the benefit of U.S. federal and state deferred tax assets due to pre-tax losses.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Cash provided by operating activities increased $270 million to $541 million for the year ended December 31, 2024, compared to $271 million for the year ended December 31, 2023. The increase in cash provided by operating activities was driven by year-over-year improvements in changes in operating assets and liabilities, partially offset by a decrease of $52 million of cash proceeds from interest rate swap settlements year-over-year.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedMD&A
Year Ended December 31, (Dollars in millions) 2025 2024 % Change Revenue $ 4,715 $ 4,439 6% Cost of sales 2,122 2,003 1,931 4% % of revenue 45 % 44 % 6% Gross profit 2,593 2,436 6% Research and development 368 344 327 5% % of revenue 8 % 7% Marketing, selling and administrative 1,430 1,314 1,285 2% % of revenue 30 % 29% 9% Amortization of intangible assets 543 527 548 (4)% 3% Asset impairment, restructuring and other special charges 237 150 127 18% Goodwill impairment — 1,042 NM 58% Gain on divestiture — (640) — NM Interest expense, net of capitalized interest 220 235 277 (15)% (6)% Other expense, net 19 18 75 (76)% Income (loss) 6% (Loss) income before income taxes (224) 488 (1,195) NM Income tax expense 8 150 36 NM (95)% Net (loss) income (loss) $ (232) $ 338 $ (1,231) NM
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
While we believe the estimates and assumptions underlying our fair value estimates were reasonable in view of all available information, significant Significant changes to any of these significant judgments estimates could have resulted result in a different amount of goodwill being allocated to our aqua business a disposal group, and if so, consequently, would have impacted impact the amount of the any pre-tax gain or loss recognized.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
As In recent years we have incurred pre-tax losses in the U.S., and as a result, result we have concluded that it is “more likely than not” that a portion of the our U.S. deferred tax assets will not be utilized, and have recorded valuation allowances of $218 million and $289 million, respectively, against these deferred tax assets. utilized.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
This can be a result of various factors, such as end customer demand, new customer contracts, initial stocking of new products, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, blackout shipping periods due to system downtime, implementations and integrations and procedures and environmental factors beyond our control.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
(Dollars in millions) Revenue Price FX Rate Volume Divestiture Total Pet Health $ 2,143 3% 2,300 2% —% (1)% 5% —% 2% 7% Farm Animal 2,250 2,362 2% (1)% 2% 1% 6% (4)% (1)% 5% Contract Manufacturing and Other 46 10% 53 15% Total $ 4,439 3% (1)% —% 4,715 2% 1% 5% (2)% —% 6%
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Amounts recorded to asset impairment, restructuring and other special charges during the year ended December 31, 2024, included a $53 million impairment charge related to the write-off of a pet health IPR&D asset, $44 million of costs associated with the restructuring plan discussed above, 2024 Restructuring Plan, $18 million of acquisition and divestiture-related charges, primarily associated with our aqua business divestiture, and $15 million of asset impairments tied to the financial difficulties of our former contract manufacturing supply partner, TriRx, the largest of which was a $12 million impairment of a contract asset related to a favorable supply agreement. TriRx Speke.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Our contractual obligations and commitments as of December 31, 2024, 2025, are primarily comprised of long-term debt obligations, operating leases, including a 25-year lease commitment that will commence in 2025 for our new corporate headquarters in Indianapolis, Indiana, both expected principal and interest obligations, leases and purchase obligations.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Our With a heritage dating back to 1954, we operate our business in a single segment within the animal health industry, offering a diverse product portfolio of approximately 200 brands brands, which helps make us a trusted partner to pet owners, veterinarians and farm animal producers.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Other expense, net for the year years ended December 31, 2025 and 2024, primarily consisted of foreign currency exchange losses and an $8 million write-down of the retained equity interest in our previously divested BiomEdit R&D platform (see Note 4. losses.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
(in millions) Net cash provided by (used for): 2025 2024 2023 $ Change Operating activities $ 560 $ 541 $ 271 $ 270 19 Investing activities (279) 1,158 (169) 1,327 (1,437) Financing activities (275) (1,492) (83) (1,409) 1,217 Effect of exchange rate changes on cash and cash equivalents 71 (91) (12) (79) 162 Net increase in cash and cash equivalents $ 77 $ 116 $ 7 $ 109 (39)
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Cash used for financing activities was $275 million for the year ended December 31, 2025, compared to $1,492 million for the year ended December 31, 2024, compared to $83 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
We recorded a pre-tax gain on divestiture of $640 million, while income tax expense associated with this gain was approximately $170 million, a majority of which is payable million in 2025. 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesMD&A
If Nonetheless, if any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ELAN/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.